GYRE THERAPEUTICS, INC. (GYRE) Cash Flow Statement
GYRE THERAPEUTICS, INC. (GYRE) generated -$4.9M of operating cash flow over the twelve months to 2026-06-30, spent $1.2M on capital expenditure and had free cash flow of -$6.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GYREGYRE THERAPEUTICS, INC.Follow GYRE — free
—
Price chart with a free account
- Market cap
- 652.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2018 Dec 18 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -83.7 | -64.2 | -40.6 | -6.4 | -28.6 | -55.0 | -83.8 | 10.7 | 25.9 | -3.6 | 1.0 | -4.9 | |
| Capital expenditure | 1.4 | 0.3 | 0.0 | 0.0 | 0.4 | — | 0.8 | 5.0 | 8.5 | 2.3 | 1.2 | -1.2 | |
| Free cash flow | -85.1 | -64.6 | -40.7 | -6.4 | -28.9 | — | -84.6 | 5.7 | 17.4 | -6.0 | -0.2 | -6.1 | |
| Dividends paid | — | — | — | — | — | — | — | 45.0 | — | — | — | — | |
| Stock-based compensation | 8.5 | 7.8 | 0.3 | 0.2 | 2.6 | 3.6 | 3.4 | 13.4 | 7.3 | 0.8 | 7.2 | — |
USD millions · SEC XBRL
GYRE THERAPEUTICS, INC. — questions
- What is GYRE THERAPEUTICS, INC.'s operating cash flow?
- -$4.9M over the twelve months to 2026-06-30.
- How much does GYRE THERAPEUTICS, INC. spend on capital expenditure?
- $1.2M over the twelve months to 2026-06-30.
- What is GYRE THERAPEUTICS, INC.'s free cash flow?
- -$6.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from GYRE THERAPEUTICS, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.